Ulipristal acetate therapy for uterine myoma: A clinical morphological trend

References

[1] Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лечения: монография, М., 2013.

[2] Chabbert-Buffet N., Meduri G., Bouchard P. et al. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update. 2005; 11: 293-307.

[3] Williams A.R.W., Critchley H.O.D., Osei J. et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum. Reprod. 2007; 22: 1696-704.

[4] Chwalisz K., Perez M.C., Demanno D. et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr. Rev. 2005; 26: 423-38.

[5] Mutter G.L., Bergeron C., Deligdisch L. et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008; 21: 591-8.

[6] Donnez J., Tomaszewski J., Vazquez F. et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. TV Engl. J. Med. 2012; 366: 421-32.

[7] Donnez J., Tatarchuk T.F., Bouchard P. et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. TV Engl. J. Med. 2012; 366: 409-20.

[8] Mutter G.L., Bergeron C., Deligdisch L. et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008; 21: 591-8.

[9] Home F.M., Blithe D.L. Progesterone receptor modulators and the endometrium: changes and consequences. Hum. Reprod. Update. 2007; 13: 567-80.

RIGHTS & PERMISSIONS

Eco-Vector